To evaluate the effect of Souvenaid on cognitive function in drug-naïve patients with mild Alzheimer’s disease over a 12-week period.
Souvenir I study was a multinational, randomised, controlled, double-blind trial conducted in 225 drug-naïve patients with mild Alzheimer’s disease. Patients had a MMSE of 20-26 inclusive. Patients were randomised to receive Souvenaid (n=106) or an isocaloric control drink (n=106) for 12 weeks.
Adapted from Scheltens P, et al. (2010) and de Wilde MC, et al. (2011)
At week 12, the Souvenaid group demonstrated a significant improvement in the delayed verbal recall task versus the control group (p=0.021), 40% of the Souvenaid group experienced an improvement in WMS-r delayed recall compared with 24% in the control group. There was no significant change in scores on the modified ADAS-cog in either group. Souvenaid was as well tolerated as the control drink and product compliance was high (94%). The drop-out rate in the study was low: 6.6% and 4.8% in the first 12 weeks.
Souvenaid is well tolerated and improves memory performance in mild Alzheimer’s disease patients.